Danaher (NYSE:DHR) Given New $268.00 Price Target at Robert W. Baird

Danaher (NYSE:DHR) had its target price decreased by equities research analysts at Robert W. Baird from $277.00 to $268.00 in a research note issued to investors on Tuesday. The brokerage presently has an “overweight” rating on the conglomerate’s stock. Robert W. Baird’s price target suggests a potential upside of 7.91% from the company’s previous close.

A number of other research firms have also recently weighed in on DHR. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a report on Friday, December 13th. Barclays reduced their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Citigroup dropped their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, Evercore ISI raised their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $285.81.

Danaher Stock Performance

NYSE DHR traded down $2.24 during trading hours on Tuesday, hitting $248.35. The company had a trading volume of 2,393,338 shares, compared to its average volume of 2,872,787. The business has a fifty day simple moving average of $235.75 and a 200-day simple moving average of $253.65. The firm has a market cap of $179.38 billion, a P/E ratio of 47.41, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher has a fifty-two week low of $225.42 and a fifty-two week high of $281.70.

Hedge Funds Weigh In On Danaher

A number of institutional investors have recently modified their holdings of the stock. Heck Capital Advisors LLC acquired a new position in Danaher during the 4th quarter worth $27,000. Decker Retirement Planning Inc. bought a new stake in shares of Danaher during the 4th quarter valued at $31,000. Golden State Wealth Management LLC acquired a new position in shares of Danaher in the 4th quarter valued at $31,000. Strategic Financial Concepts LLC bought a new position in shares of Danaher in the 4th quarter worth $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher during the third quarter worth $39,000. 79.05% of the stock is owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.